--- title: 32 Biosciences Reviews meta_title: '32 Biosciences Reviews 2026: Details, Pricing, & Features | G2' meta_description: Filter reviews by the users' company size, role or industry to find out how 32 Biosciences works for a business like yours. date_modified: '2026-07-01' parent_category: name: Artificial Intelligence url: https://www.g2.com/categories/artificial-intelligence --- # 32 Biosciences Reviews **Vendor:** 32 Biosciences **Category:** [Emerging AI Software](https://www.g2.com/categories/emerging-ai-software) ## About 32 Biosciences 32 Biosciences is a biotechnology company dedicated to pioneering gut mucosal-immune science to prevent and treat gastrointestinal (GI) diseases. Focusing initially on the colon, the company addresses significant unmet medical needs by developing first-in-class therapeutics and innovative discovery platforms. Recognizing the critical role of the gastrointestinal mucosal barrier in infection risk, chronic disease, and microbiome balance, 32 Biosciences aims to restore and protect the GI mucosal-immune system to enhance patient outcomes. Key Features and Functionality: - CS Therapeutic Pipeline: This Mucosal Immune Modulator (MIM) therapeutic approach is designed to restore and protect the mucosal-immune barrier in the gastrointestinal tract. The lead asset, CS-0003, is a first-in-class MIM intended to buffer the GI tract by coating and protecting the mucosal barrier, suppressing bacterial virulence, and modulating the mucosal-immune system. - GB: GI Discovery Platform: A metabolomics-based platform that quantifies signatures of gut mucosal function and host-microbe interactions. This platform supports therapeutic discovery, development, and clinical decision-making by providing insights into the functional state of the gut mucosal-immune system. Primary Value and Solutions: 32 Biosciences addresses the critical gap in gastrointestinal medicine by focusing on the biology that drives GI diseases. Traditional tools and therapies often overlook the destabilization of the gut mucosal-immune barrier, leading to surgical infections, chronic inflammation, and recurrent conditions. By restoring and protecting this barrier, the company aims to prevent and treat severe GI diseases, improve patient outcomes, and transform standards of care. Their mission encompasses preventing GI surgical site infections, intercepting chronic inflammatory diseases earlier, reducing recurrence risks, and developing therapies that restore mucosal-immune stability. Through their innovative therapeutic pipeline and discovery platform, 32 Biosciences strives to deliver solutions that provide predictability, protection, and better outcomes for patients facing serious GI diseases. - [View 32 Biosciences pricing details and edition comparison](https://www.g2.com/products/32-biosciences/reviews?section=pricing&secure%5Bexpires_at%5D=2026-07-01+06%3A51%3A58+-0500&secure%5Bsession_id%5D=b95ba200-7ef3-4832-9cd1-541f880bd565&secure%5Btoken%5D=079bb80a6aa12852a3c9566ccd804fa2a2f54b9d77d320063e5ae34579417161&format=llm_user)